文献速递消化道肿瘤与早癌消化内镜食管胃疾病与幽门螺杆菌

胃炎分期在内镜随访中用于胃癌二级预防:一项1755例患者的前瞻性5年研究

Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients.
PubMed 文献 · Gut · 2018-01-06

该前瞻性队列纳入1755例连续消化不良患者,行胃黏膜定点活检及OLGA分期并评估幽门螺杆菌感染,中位随访55个月。结果显示上皮内瘤变仅发生于III-IV期患者,III期和IV期风险分别为36.5/1000人年和63.1/1000人年,0-II期风险为零。结论认为OLGA分期可可靠预测胃上皮内瘤变风险,但晚期患者根除幽门螺杆菌后风险仍未消除。

要点

  • OLGA III-IV期患者发生胃上皮内瘤变的风险显著升高,0-II期风险为零。
  • III期风险为36.5/1000人年,IV期为63.1/1000人年。
  • 晚期患者根除幽门螺杆菌后仍不能消除瘤变进展风险。

核心结论

  • 该前瞻性研究证实OLGA分期能可靠预测胃上皮内瘤变的发生风险。
  • 尽管幽门螺杆菌初治阴性者未发生瘤变,但晚期(III-IV期)患者根除幽门螺杆菌后并未消除瘤变进展风险。

研究设计与样本

  • 前瞻性队列研究,纳入1755例连续消化不良患者,基线行食管胃十二指肠镜及胃黏膜定点活检、OLGA分期和幽门螺杆菌感染评估。
  • 患者中位随访55个月,II、III、IV期患者接受第二次内镜/再分期,0期和I期患者进行临床及病历深入随访。
  • 终点为再分期时的OLGA分期和胃上皮内瘤变的发生。

主要发现

  • 基线时77.6%患者为0期,14.4%为I期,5.1%为II期,2.1%为III期,0.85%为IV期。
  • 基线检出幽门螺杆菌感染603例,其中602例成功根除;220例有根除史;932例为幽门螺杆菌初治阴性。
  • 新发瘤变(患病率0.4%;低级别上皮内瘤变4例、高级别上皮内瘤变1例、胃癌2例)仅发生于III-IV期患者。
  • 0、I、II期患者上皮内瘤变风险为零(95%CI 0至0.4);III期风险为36.5/1000人年(95%CI 13.7至97.4);IV期风险为63.1/1000人年(95%CI 20.3至195.6)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Operative link on gastritis assessment (OLGA) staging for gastritis ranks the risk for gastric cancer (GC) in progressive stages (0-IV). This prospective study aimed at quantifying the cancer risk associated with each gastritis stage. DESIGN: A cohort of 1755 consecutive patients with dyspepsia underwent initial (T-0) oesophagogastroduodenoscopy with mapped gastric biopsies, OLGA staging and assessment of Helicobacter pylori infection. Patients were followed for 55 months (median); patients with stages II III and IV underwent a second endoscopy/restaging (T-1), and those with stages 0 and I were followed clinically and through in-depth clinical and record checking. Endpoints were OLGA stage at T-1 and development of gastric epithelial neoplasia. RESULTS: At T-0, 77.6% of patients had stage 0, 14.4% stage I, 5.1% stage II, 2.1% stage III and 0.85% stage IV. H. pylori infection was detected in 603 patients at T-0 and successfully eradicated in 602 of them; 220 had a documented history of H. pylori eradication; and 932 were H. pylori naïve-negative. Incident neoplastic lesions (prevalence=0.4%; low-grade intraepithelial neoplasia (IEN)=4; high-grade IEN=1; GC=2) developed exclusively in patients with stages III-IV. The risk for epithelial neoplasia was null in patients at stages 0, I and II (95% CI 0 to 0.4), 36.5 per 1000 person-years in patients at stage III (95% CI 13.7 to 97.4) and 63.1 per 1000 person-years in patients at stage IV (95% CI 20.3 to 195.6). CONCLUSIONS: This prospective study confirms that OLGA staging reliably predicts the risk for development of gastric epithelial neoplasia. Although no neoplastic lesions arose in H. pylori-naïve patients, the H. pylori eradication in subjects with advanced stages (III-IV) did not abolish the risk for neoplastic progression.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Rugge M, Meggio A, Pravadelli C, et al. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut. 2018. PMID: 29306868. doi:10.1136/gutjnl-2017-314600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。